Therapeutic target
Improvement of the symptomatology
Therapy recommendations
- Phosphate binders (dose adjustment according to serum phosphate level).
- If necessary, calcitriol substitution* (lowers the level of intact parathyroid hormone); indication: renal insufficiency (renal weakness; increase in the concentration of urinary substances) with elevated parathyroid hormone levels.
- Calcimimetic (parathyroid hormone release ↓); Indication: therapy of secondary hyperparathyroidism (parathyroid hyperfunction) in hemodialysis patients.
- See also under “Further therapy“.
* Calcitriol (synonyms: 1α,25(OH)2-cholecalciferol (1α,25(OH)2vitamin D3) or 1,25(OH)2D3 for short) is a highly potent secosteroid with structural similarity to steroid hormones. It is the physiologically active form of the prohormone vitamin D3. It is hydroxylated from 25(OH)vitamin D3 by 1α-hydroxylase, primarily in the kidneys but also in other tissues.
